Results 41 to 50 of about 397,699 (411)

Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin

Cardio-Oncology, 2020
Background Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity.
Jieli Li, Hui-Ming Chang, Jose Banchs, Dejka M. Araujo, Saamir A. Hassan, Elizabeth A. Wagar, Edward T. H. Yeh, Qing H. Meng   +7 more
doaj   +1 more source

Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. [PDF]

PLoS ONE, 2015
Doxorubicin has been shown to inhibit proliferation of cancer cells through proteolytic activation of CREB3L1 (cAMP response element binding protein 3-like 1), a transcription factor synthesized as a membrane-bound precursor.
Bray Denard, Andrea Pavia-Jimenez, Weina Chen, Noelle S Williams, Harris Naina, Robert Collins, James Brugarolas, Jin Ye   +7 more
doaj   +1 more source

Exposure to Doxorubicin Modulates the Cardiac Response to Isoproterenol in Male and Female Mice

Pharmaceuticals, 2023
Sex is a salient risk factor in the development of doxorubicin-induced cardiotoxicity. Sex differences in the heart’s ability to respond to hypertrophic stimuli in doxorubicin-exposed animals have not been reported.
Kevin Agostinucci, Marianne K. O. Grant, Wongel Melaku, Chandini Nair, Beshay N. Zordoky   +4 more
doaj   +1 more source

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials [PDF]

, 2010
Background: We conducted a systematic review and meta-analysis to clarify the risk of early and late cardiotoxicity of anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma.Methods: Randomized controlled ...
Canney, Peter, Cornelius, Victoria, Jones, Alison, Lesley, A. Smith, Levitt, Gill, Plummer, Christopher J., Verrill, Mark   +6 more
core   +3 more sources

Trisulfide bond–mediated doxorubicin dimeric prodrug nanoassemblies with high drug loading, high self-assembly stability, and high tumor selectivity

Science Advances, 2020
Trisulfide bond enhances the stability and GSH sensitivity of doxorubicin dimeric prodrug nanoassemblies. Rational design of nanoparticulate drug delivery systems (nano-DDS) for efficient cancer therapy is still a challenge, restricted by poor drug ...
Yinxian Yang, Bingjun Sun, Shiyi Zuo, Ximu Li, Shuang Zhou, Lingxiao Li, C. Luo, Hongzhuo Liu, M. Cheng, Yongjun Wang, Shujun Wang, Zhonggui He, Jin Sun   +12 more
semanticscholar   +1 more source

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

BMC Cancer, 2008
Background Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells.
Zhou Chun-lei, Xu Qiong, Liang Yu, Jia Jing, Lu Rong, Chen Li-juan, Zhu Zhi-feng, Wang Li, Wang Song, Yao Zhi   +9 more
doaj   +1 more source

Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury

Cancer Innovation, 2023
Background Doxorubicin is a widely used cytotoxic chemotherapy agent for treating different malignancies. However, its use is associated with dose‐dependent cardiotoxicity, causing irreversible myocardial damage and significantly reducing the patient's ...
Qingling Zhang, Yunpeng Zhang, Bingxin Xie, Daiqi Liu, Yueying Wang, Zandong Zhou, Yue Zhang, Emma King, Gary Tse, Tong Liu   +9 more
doaj   +1 more source

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. [PDF]

, 2017
Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target.
DeVere White, Ralph W, Duan, Zhijian, Ho, Pui Yan, Jian, Chao, Lam, Kit S, Lara, Primo N, Qiu, Jing-Xin, Tu, Mei-Juan, Wun, Theodore, Yu, Ai-Ming, Yu, Ai-Xi, Zhang, Qianyu   +11 more
core   +1 more source

Use of in vitro human keratinocyte models to study the effect of cooling on chemotherapy drug-induced cytotoxicity [PDF]

, 2014
A highly distressing side-effect of cancer chemotherapy is chemotherapy-induced alopecia (CIA). Scalp cooling remains the only treatment for CIA, yet there is no experimental evidence to support the cytoprotective capacity of cooling. We have established
Andrew Collett, Bodo, Boelsma, Boukamp, Breed, Brunsvig, Bulow, Christopher Dunnill, Corina J. van den Hurk, Dean, Deyrieux, Georgopoulos, Gregory, Grevelman, Inui, Itami, Itoh, Janssen, Janssen, Kayamba, Komen, Lane, Liu, Luanpitpong, Manon M. Komen, Margulis, Munstedt, Nabholtz, Nikolaos T. Georgopoulos, Omar Hussain, Paus, Protiere, Roh, van den Hurk, Wafaa Al-Tameemi, Wang, Watanabe   +36 more
core   +1 more source

The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a

Circulation Research, 2020
Supplemental Digital Content is available in the text. Rationale: Doxorubicin is one of the most potent antitumor agents available; however, its clinical use is restricted because it poses a risk of severe cardiotoxicity.
Dong Han, Yongjun Wang, Yabin Wang, Xinchun Dai, Tingwen Zhou, Jiangwei Chen, B. Tao, Jibin Zhang, F. Cao   +8 more
semanticscholar   +1 more source